CME / ABIM MOC / CE

Chronic Leukemias

Authors: Michael J. Mauro, MD; Jerald Radich, MD; Hagop M. Kantarjian, MD; Nitin Jain, MD; Anthony R. Mato, MD, MSCE; Shilpa Paul, PharmD, BCOP; Courtney D. DiNardo, MD, MSCE
CME / ABIM MOC / CE Released: 3/2/2023
Valid for credit through: 3/2/2024

Credits Available

Physicians - maximum of 1.50 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 1.50 ABIM MOC points

Nurses - 1.50 ANCC Contact Hour(s) (1.25 contact hours are in the area of pharmacology)

Pharmacists - 1.50 Knowledge-based ACPE (0.150 CEUs)

IPCE - 1.50 Interprofessional Continuing Education (IPCE) credit

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologist/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), benign hematologic diseases, and other related conditions.

The goal of this activity is that learners will be better able to personalize treatment for patients with chronic leukemias in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Recent clinical trial data on treatment strategies for chronic leukemias in the frontline or R/R settings
Have greater competence related to
- Selecting evidence-based treatment for patients with chronic leukemias in the frontline and R/R disease
- Mitigating adverse events associated with current therapies for patients with chronic leukemias
Demonstrate greater confidence in their ability to
- Personalize treatment for patients with chronic leukemias in an interprofessional team-based environment

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Michael J. Mauro, MD, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Novartis; Pfizer, Inc.; Takeda
Research funding from: Bristol Myers Squibb Company; Novartis; SPARC; Sun Pharmaceutical Industries, Ltd.; Takeda

Jerald Radich, MD

Professor
Clinical Research Division
Kurt Enslein Endowed Chair
Fred Hutchinson Cancer Center
Seattle, Washington

Disclosures

Jerald Radich, MD, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Cepheid; HTG Therapeutics; Novartis; NuProbe USA Inc.

Hagop M. Kantarjian, MD

Professor and Chair
Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Hagop M. Kantarjian, MD, has no relevant financial relationships.

Nitin Jain, MD

Associate Professor of Medicine
Department of Leukemia
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Nitin Jain, MD, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Adaptive Biotechnologies; AstraZeneca Pharmaceuticals, LP; BeiGene (Beijing) Co., Ltd.; Bristol Myers Squibb Company; CareDX; Cellectis; Genentech; Gilead Sciences, Inc.; Ipsen; Janssen; Kite Pharma, Inc.; MEI Pharma, Inc.; Pharmacyclics, Inc.; Precision Biosciences; TG Therapeutics, Inc.
Research funding from: AbbVie, Inc.; Adaptive Biotechnologies; ADC Therapeutics; Aprea Therapeutics; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Cellectis; Dialectic Therapeutics; Fate Therapeutics, Inc.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Kite Pharma, Inc.; Loxo Oncology; Medisix Therapeutics Pte. Ltd.; Mingsight Pharmaceuticals Inc; Newave Pharmaceuticals Inc.; NovalGen; Pfizer, Inc.; Pharmacyclics, Inc.; Precision Biosciences; Servier; Takeda; TransThera Biosciences Co. Ltd.
Contracted researcher for: AbbVie, Inc.; Adaptive Biotechnologies; ADC Therapeutics; Aprea Therapeutics; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Cellectis; Dialectic therapeutics; Fate Therapeutics, Inc.; Genentech; Gilead Sciences, Inc.; Incyte Corporation; Kite Pharma, Inc.; Loxo Oncology; Medisix Therapeutics Pte. Ltd.; Mingsight Pharmaceuticals Inc.; Newave Pharmaceuticals Inc.; NovalGen; Pfizer, Inc.; Pharmacyclics, inc.; Precision Biosciences; Servier; Takeda; TransThera Biosciences Co. Lt.

Anthony R. Mato, MD, MSCE

Director, CLL Program
Memorial Sloan Kettering Cancer Center
New York, New York

Disclosures

Anthony R. Mato, MD, MSCE, has no relevant financial relationships.

Shilpa Paul, PharmD, BCOP

Clinical Pharmacy Specialist - Leukemia
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Shilpa Paul, PharmD, BCOP, has the following relevant financial relationships:
Consultant or advisor for: Amgen, Inc.; Novartis

Courtney D. DiNardo, MD, MSCE

Associate Professor
Department of Leukemia
Division of Cancer Medicine
University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Courtney D. DiNardo, MD, MSCE, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Agios Pharmaceuticals; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Genentech; Genmab; Novartis; Notable Labs; Servier; Takeda
Research funding from: AbbVie, Inc.; Agios Pharmaceuticals; Astex Pharmaceuticals; Bristol Myers Squibb Company; Calithera Biosciences; Celgene Corporation; Cleave Therapeutics; Foghorn Therapeutics; Immune-Onc Therapeutics; Loxo Oncology

Editor

Heather P. Friedman, MPH

Medical Education Director, Medscape, LLC

Disclosures

Heather P. Friedman, MPH, has no relevant financial relationships.

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

For Physicians

Medscape, LLC designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 1.25 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 1.50 contact hour(s) (0.150 CEUs) (Universal Activity Number JA0007105-0000-23-102-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Chronic Leukemias

Authors: Michael J. Mauro, MD; Jerald Radich, MD; Hagop M. Kantarjian, MD; Nitin Jain, MD; Anthony R. Mato, MD, MSCE; Shilpa Paul, PharmD, BCOP; Courtney D. DiNardo, MD, MSCEFaculty and Disclosures

CME / ABIM MOC / CE Released: 3/2/2023

Valid for credit through: 3/2/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (PRO)

Dr Mauro discusses the advantages of TFR as the goal of frontline treatment for chronic myeloid leukemia (CML).
Michael J. Mauro, MD

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (CON)

Dr Radich explores the drawbacks of aiming for TFR as the goal of frontline CML treatment.
Jerald Radich, MD

Sequencing Treatments in Relapsed/Refractory CML

Dr Kantarjian shares his insights for effectively sequencing tyrosine kinase inhibitors in R/R CML.
Hagop M. Kantarjian, MD

Frontline CLL Management: Chemoimmunotherapy vs BTK Inhibitors

Dr Jain updates us on recent advances in the frontline management of chronic lymphocytic leukemia (CLL).
Nitin Jain, MD

Management of Relapsed/Refractory CLL

Dr Mato reviews the current and emerging management options for R/R CLL.
Anthony R. Mato, MD, MSCE

Managing Oral Medications in Chronic Leukemias

Dr Paul explores best practices for selecting and managing oral therapies for chronic leukemias.
Shilpa Paul, PharmD, BCOP

Learning Feedback Questions

Please answer these questions to complement your learning experience.

Page 1 of 9

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Michael J. Mauro, MD

Jerald Radich, MD

Hagop M. Kantarjian, MD

Nitin Jain, MD

Anthony R. Mato, MD, MSCE

Shilpa Paul, PharmD, BCOP

Courtney D. DiNardo, MD, MSCE

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Chronic Leukemias

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Michael J. Mauro, MD

Jerald Radich, MD

Hagop M. Kantarjian, MD

Nitin Jain, MD

Anthony R. Mato, MD, MSCE

Shilpa Paul, PharmD, BCOP

Courtney D. DiNardo, MD, MSCE

Editor

Heather P. Friedman, MPH

Compliance Reviewer

Amanda Jett, PharmD, BCACP

Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Chronic Leukemias

Contents of This CME Activity

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (PRO)

Treatment-Free Remission as the Goal of Frontline CML Treatment: A Debate (CON)

Sequencing Treatments in Relapsed/Refractory CML

Frontline CLL Management: Chemoimmunotherapy vs BTK Inhibitors

Management of Relapsed/Refractory CLL

Managing Oral Medications in Chronic Leukemias

Learning Feedback Questions